Key result
Levosimendan reduces ischemia/reperfusion injury and inhibits cardiomyocyte apoptosis across preclinical models.
Why the study?
Despite levosimendan's approval for cardiac failure, its superiority over β-adrenergic agonists for long-term survival is uncertain, and the link between its effects on ischemia/reperfusion injury and cardiomyocyte apoptosis is not well established.
Does levosimendan reduce ischemia/reperfusion injury and inhibit cardiomyocyte apoptosis?
Does levosimendan reduce ischemia/reperfusion injury and inhibit cardiomyocyte apoptosis?
This review highlights the potential of levosimendan to reduce ischemia/reperfusion injury and inhibit cardiomyocyte apoptosis, extending its therapeutic relevance beyond positive inotropy in heart failure.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in ischemia/reperfusion injury; leaves open molecular mechanisms and requires prospective validation.
Levosimendan is a calcium sensitizer with positive inotropic and vasodilating properties. It increases the sensitivity of troponin C for calcium, opens adenosine triphosphate-dependent potassium K(+) channels and inhibits phosphodiesterase III. Levosimendan is approved for use in cardiac failure but large clinical trials have raised doubts whether levosimendan is superior to β-adrenergic agonists regarding long-term survival of patients. Despite this controversy, there is growing evidence of beneficial effects of levosimendan in ischemia/reperfusion (I/R) injury due to its effect on K(+) channels. As a consequence, patents on K(+) channel agonists have been granted recently for reducing injury in organs or tissue in transplants and trauma therapy. Moreover, experimental studies and clinical trials have shown that levosimendan effectively inhibits cardiomyocyte apoptosis. The underlying molecular mechanism is currently unclear. However, it is tempting to assume that levosimendan inhibits cardiomyocyte apoptosis due to its beneficial effect on I/R injury. However, the link between these two phenomena has not been well established. This review summarizes experimental studies and clinical trials on the effects of levosimendan in I/R injury and apoptosis also discussing recent patents.
No takes yet. Share an insight, caveat, or question.
Scheiermann et al. (2011) conducted a review in Ischemia/reperfusion injury and apoptosis. Levosimendan was evaluated. Levosimendan demonstrates beneficial effects in ischemia/reperfusion injury and effectively inhibits cardiomyocyte apoptosis, although the underlying molecular mechanisms remain unclear.
Synapse has enriched 10 related papers. Consider them for comparative context: